Discovery of Potent Small-Molecule SIRT6 Activators: Structure–Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity
Authors:
- 12 August 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (18) , 10474-10495
Abstract
SIRT6 activation is thought to be a promising target for the treatment of many diseases, particularly cancer. Herein, we report the discovery of a series of new small molecule SIRT6 activators. Structure-activity relationship analyses led to the identification of the most potent compound, 2-(1-benzofuran-2-yl)-N-(diphenylmethyl) quinolone-4-carboxamide (12q), which showed an EC1.5 value of 0.58 ± 0.12 μM and an EC50 value of 5.35 ± 0.69 μM against SIRT6-dependent peptide deacetylation in Fluor de Lys assay. It exhibited weak or no activity against other HDAC family members as well as 415 kinases, indicating a good selectivity for SIRT6. 12q significantly inhibited the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro. It also markedly suppressed the tumor growth in a PDAC tumor xenograft model. This compound showed attractive pharmacokinetic properties. Overall, 12q could be a good lead compound for the treatment of PDAC, and it is worthy of further study.Keywords
Funding Information
- National Natural Science Foundation of China (21772130, 81773633, 81930125)
- Department of Science and Technology for Social Development (2018ZX09201018, 2018ZX09711002-011-019, 2018ZX09711002-014-002, 2018ZX09711003-003-006, 2019ZX09301-135)
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZY2017202, ZYGD18001)
This publication has 56 references indexed in Scilit:
- Sirtuin-6–Dependent Genetic And Epigenetic Alterations Are Associated With Poor Clinical Outcome in Hepatocellular Carcinoma PatientsHepatology, 2013
- Comparative Study of the Affinity and Metabolism of Type I and Type II Binding Quinoline Carboxamide Analogues by Cytochrome P450 3A4Journal of Medicinal Chemistry, 2011
- RETRACTED: Human SIRT6 Promotes DNA End Resection Through CtIP DeacetylationScience, 2010
- Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride SynthesisCell Metabolism, 2010
- The Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1αCell, 2010
- Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma bruceiChemMedChem, 2009
- SIRT6 Links Histone H3 Lysine 9 Deacetylation to NF-κB-Dependent Gene Expression and Organismal Life SpanCell, 2009
- SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatinNature, 2008
- Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetesNature, 2007
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997